Sept 2019: Cardio Diagnostics receives a Phase I NIH SBIR

Cardio Diagnostics received $225K in National Institutes of Health (NIH) funding to further develop our integrated genetic-epigenetic coronary heart disease risk screening technology.

No Comments

Sorry, the comment form is closed at this time.